Title
Festina lente: Hydroxychloroquine, COVID-19 and the role of the rheumatologist
Date Issued
01 June 2020
Access level
open access
Resource Type
review
Author(s)
Graef E.R.
Liew J.W.
Putman M.S.
Simard J.F.
Sirotich E.
Berenbaum F.
Duarte-GarcÃa A.
Grainger R.
Harrison C.
Konig M.F.
Korsten P.
Proulx L.
Richards D.P.
Robinson P.C.
Sattui S.E.
Young K.J.
Kim A.H.J.
Sparks J.A.
Publisher(s)
BMJ Publishing Group
Start page
S734
End page
S736
Volume
79
Issue
6
Language
English
OCDE Knowledge area
InmunologÃa
Subjects
Scopus EID
2-s2.0-85083384822
PubMed ID
Source
Annals of the Rheumatic Diseases
ISSN of the container
00034967
Sponsor(s)
Competing interests FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma. RG reports personal fees from Pfizer, Cornerstones, Jannsen and Novartis. PK reports personal fees from GlaxoSmithKline, Sanofi-Aventis, Pfizer, Abbvie, Novartis Pharma, Eli Lilly and Bristol-Myers Squibb. AHJK reports grants from NIH (National Institutes of Health)/NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) and Rheumatology Research Foundation and personal fees from Exagen Diagnostics and GlaxoSmithKline. JAS reports grants from NIH/NIAID (National Institute of Allergy and Infectious Diseases)/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum.
Sources of information:
Directorio de Producción CientÃfica
Scopus